Mostra el registre parcial de l'element
dc.contributor.author | Moreno Torres, Marta | |
dc.contributor.author | Murguía, José Ramón | |
dc.date.accessioned | 2023-05-22T08:19:56Z | |
dc.date.available | 2023-05-22T08:19:56Z | |
dc.date.issued | 2011 | |
dc.identifier.citation | Moreno Torres, Marta Murguía, José Ramón 2011 Between Scylla and Charibdis: eIF2alpha kinases as targets for cancer chemotherapy. Clinical & Translational Oncology 13 442 445 | |
dc.identifier.uri | https://hdl.handle.net/10550/86757 | |
dc.description.abstract | The eIF2α kinases integrate translation initiation rates with nutrient availability, thus allowing cells to adapt to nutrient scarcity. Recent evidence has uncovered new functions of these kinases in tumour cell biology, ranging from regulation of cell cycle progression, maintenance of genome stability, control of apoptosis, and cell survival under nutrient stress and hypoxia. Accordingly, active eIF2α kinases modulate the antineoplasic activity of several antitumour drugs, either by exacerbating their cytotoxic effect or by promoting chemoresistance. Understanding of eIF2α kinases molecular roles may provide mechanistic insights into how tumour cells sense and adapt to nutrient restriction, thus helping to implement more effective approaches for cancer chemotherapy. | |
dc.language.iso | eng | |
dc.relation.ispartof | Clinical & Translational Oncology, 2011, vol. 13, p. 442-445 | |
dc.subject | Bioquímica | |
dc.subject | Biologia | |
dc.title | Between Scylla and Charibdis: eIF2alpha kinases as targets for cancer chemotherapy. | |
dc.type | journal article | |
dc.date.updated | 2023-05-22T08:19:56Z | |
dc.identifier.doi | 10.1007/s12094-011-0680-3 | |
dc.identifier.idgrec | 158858 | |
dc.rights.accessRights | open access |